Design Therapeutics(US:DSGN)2025-03-10 11:10Clinical Trials - Design Therapeutics initiated a Phase 1 trial of DT-216P2 for Friedreich Ataxia (FA) with patient dosing expected to begin in mid-2025[2] - The company completed dosing in the Phase 1 trial of DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) and anticipates data release in the first half of 2025[4] - The company achieved enrollment of approximately 250 patients in the FECD observational study, with 100 selected for future follow-ups[4] - Design Therapeutics plans to select a development candidate for myotonic dystrophy type-1 (DM1) in 2025[4] Financial Performance - Research and development (R&D) expenses for Q4 2024 were $12.2 million, a 10.4% increase from $11.0 million in Q4 2023[8] - General and administrative (G&A) expenses for Q4 2024 were $4.5 million, compared to $4.1 million in Q4 2023, reflecting a 9.8% increase[8] - The net loss for Q4 2024 was $13.7 million, up from a net loss of $11.8 million in Q4 2023, indicating a 16.1% increase in losses[8] - Total operating expenses for the year ended December 31, 2024, were $62.4 million, down from $78.2 million in 2023, a decrease of 20.2%[12] - The total stockholders' equity as of December 31, 2024, was $242.1 million, down from $277.7 million in 2023[14] Cash Position - Cash, cash equivalents, and marketable securities totaled $245.5 million as of December 31, 2024, expected to fund operations into 2029[8]